Your browser is no longer supported. Please, upgrade your browser.
Settings
BEAM Beam Therapeutics Inc. daily Stock Chart
BEAM [NASD]
Beam Therapeutics Inc.
Index- P/E- EPS (ttm)-1.90 Insider Own1.80% Shs Outstand52.86M Perf Week-10.65%
Market Cap1.38B Forward P/E- EPS next Y- Insider Trans- Shs Float45.85M Perf Month-
Income-86.20M PEG- EPS next Q- Inst Own18.50% Short Float- Perf Quarter-
Sales0.01M P/S114926.45 EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh-5.56 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh2.10 P/C12.44 EPS next 5Y- ROE- 52W Range18.55 - 31.80 Perf YTD39.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-17.96% Beta-
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin- 52W Low40.65% ATR3.16
Employees112 Current Ratio5.80 Sales Q/Q- Oper. Margin- RSI (14)- Volatility9.09% -
OptionableNo Debt/Eq- EPS Q/Q46.60% Profit Margin- Rel Volume0.32 Prev Close26.91
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.26M Price26.09
Recom- SMA203.06% SMA503.06% SMA2003.06% Volume397,332 Change-3.05%
Feb-11-20 07:41AM  Beam Therapeutics Announces Closing of Initial Public Offering Business Wire +9.05%
06:30AM  Beam Therapeutics Announces Multiple Scientific Advances in its Base Editing Technology Platforms Business Wire
Feb-05-20 07:05PM  Beam Therapeutics Announces Pricing of Initial Public Offering Business Wire
Jan-27-20 07:24AM  Beam Therapeutics to offer 6.25 million shares in planned IPO priced at $15 to $17 each MarketWatch
Jan-25-20 05:00AM  Bourbon and Scotch Makers Find a Common Enemy in Tariffs Bloomberg
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.